MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-05-2025
Edwards Lifesciences Corporation General and Administrative Expenses 2011-2025 | EW
General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.What these expenses include
- Salaries of administrative staff (executives, HR, accountants, legal personnel)
- Office rent and utilities
- Office equipment and IT infrastructure
- Professional services (auditors, lawyers, consultants)
- Insurance
- General administrative travel and representation expenses
- Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure - Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit - Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry - Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines
Annual General and Administrative Expenses Edwards Lifesciences Corporation
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.79 B | 1.58 B | 1.36 B | 1.49 B | 1.23 B | 1.24 B | 1.09 B | 985 M | 905 M | 851 M | 858 M | 746 M | 705 M | 642 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.79 B | 642 M | 1.11 B |
Quarterly General and Administrative Expenses Edwards Lifesciences Corporation
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 515 M | 502 M | 466 M | - | 421 M | 448 M | 428 M | - | 382 M | 410 M | 436 M | - | 377 M | 409 M | 370 M | - | 364 M | 374 M | 331 M | - | 307 M | 275 M | 308 M | - | 306 M | 308 M | 280 M | - | 270 M | 275 M | 256 M | - | 245 M | 244 M | 230 M | - | 230 M | 229 M | 213 M | - | 212 M | 214 M | 202 M | - | 222 M | 216 M | 197 M | - | 178 M | 187 M | 182 M | - | 168 M | 182 M | 177 M | - | 166 M | 163 M | 150 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 515 M | 150 M | 289 M |
General and Administrative Expenses of other stocks in the Medical devices industry
| Issuer | General and Administrative Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Abiomed
ABMD
|
334 M | - | - | $ 17.2 B |  USA |
 |
Acutus Medical
AFIB
|
14.1 M | - | -26.83 % | $ 2.62 M | USA |
 |
Allied Healthcare Products
AHPI
|
7.11 M | - | 3.58 % | $ 2.21 M | USA |
 |
GenMark Diagnostics, Inc.
GNMK
|
25.6 M | - | - | $ 1.77 B | USA |
 |
Apyx Medical Corporation
APYX
|
22.2 M | $ 3.42 | -5.0 % | $ 118 M | USA |
 |
Boston Scientific Corporation
BSX
|
5.98 B | $ 96.04 | -0.06 % | $ 141 B | USA |
 |
Obalon Therapeutics, Inc.
OBLN
|
8.78 M | - | -5.86 % | $ 30.6 M | USA |
 |
Cognyte Software Ltd.
CGNT
|
163 M | $ 9.46 | -0.89 % | $ 679 M |  Israel |
 |
Bio-Rad Laboratories
BIO
|
814 M | $ 301.9 | -0.1 % | $ 8.52 B | USA |
 |
Apollo Endosurgery
APEN
|
20.6 M | - | - | $ 475 M | USA |
 |
Conformis
CFMS
|
28.8 M | - | - | $ 16.4 M | USA |
 |
Eargo
EAR
|
54.3 M | - | - | $ 10.2 M | USA |
 |
BioSig Technologies
BSGM
|
11.6 M | - | 37.08 % | $ 85.7 M | USA |
 |
Cardiovascular Systems
CSII
|
171 M | - | 0.15 % | $ 844 M | USA |
 |
Bruker Corporation
BRKR
|
894 M | $ 47.74 | -0.79 % | $ 7.11 K | USA |
 |
Cutera
CUTR
|
63.3 M | - | -10.19 % | $ 1.99 M | USA |
 |
Abbott Laboratories
ABT
|
11.7 B | $ 124.54 | -0.25 % | $ 217 B | USA |
 |
EDAP TMS S.A.
EDAP
|
5.9 M | $ 3.31 | 11.55 % | $ 123 M |  France |
 |
CryoLife, Inc.
CRY
|
141 M | - | -4.14 % | $ 702 M | USA |
 |
Soliton, Inc.
SOLY
|
8.46 M | - | -1.42 % | $ 435 M | USA |
 |
Hancock Jaffe Laboratories, Inc.
HJLI
|
4.88 K | - | -1.98 % | $ 98.3 M | USA |
 |
Itamar Medical Ltd.
ITMR
|
8.5 M | - | 0.03 % | $ 1.58 B | Israel |
 |
Misonix, Inc.
MSON
|
18 M | - | - | $ 462 M | USA |
 |
Neovasc
NVCN
|
14.7 M | - | - | $ 111 M |  Canada |
 |
Dynatronics Corporation
DYNT
|
8.46 M | - | 14.99 % | $ 929 K | USA |
 |
Intersect ENT, Inc.
XENT
|
98.6 M | - | - | $ 955 M | USA |
 |
InMode Ltd.
INMD
|
8.41 M | $ 14.56 | 0.62 % | $ 1.15 B | Israel |
 |
IRIDEX Corporation
IRIX
|
8.75 M | $ 1.23 | 7.89 % | $ 19.8 M | USA |
 |
Second Sight Medical Products
EYES
|
806 K | - | -0.97 % | $ 54.4 M | USA |
 |
Align Technology
ALGN
|
1.76 B | $ 156.76 | -0.68 % | $ 11.7 B | USA |
 |
NanoVibronix
NAOV
|
3.46 M | - | - | $ 1.08 M | USA |
 |
Accuray Incorporated
ARAY
|
47.9 M | $ 0.84 | -2.14 % | $ 86.3 M | USA |
 |
IRadimed Corporation
IRMD
|
15.9 M | $ 97.39 | 0.34 % | $ 1.23 B | USA |
 |
LivaNova PLC
LIVN
|
526 M | $ 62.64 | -0.7 % | $ 3.4 B |  Britain |
 |
Avinger
AVGR
|
14.1 M | - | -20.74 % | $ 369 K | USA |
 |
ClearPoint Neuro
CLPT
|
12 M | $ 13.97 | -3.57 % | $ 378 M | USA |
 |
FONAR Corporation
FONR
|
23.5 M | $ 14.45 | -0.55 % | $ 94.7 M | USA |
|
LENSAR
LNSR
|
26.5 M | $ 12.01 | - | $ 138 M | USA |
 |
AxoGen
AXGN
|
39 M | $ 32.13 | -1.55 % | $ 1.42 B | USA |
 |
Axonics Modulation Technologies
AXNX
|
40.2 M | - | - | $ 3.31 B | USA |
 |
GBS
GBS
|
8.88 M | - | -0.57 % | $ 7.12 M | USA |
 |
CONMED Corporation
CNMD
|
117 M | $ 40.2 | 0.07 % | $ 1.24 B | USA |
 |
OrthoPediatrics Corp.
KIDS
|
103 M | $ 17.24 | -1.0 % | $ 398 M | USA |
 |
Globus Medical
GMED
|
981 M | $ 87.98 | -0.6 % | $ 11.9 B | USA |
 |
Integra LifeSciences Holdings Corporation
IART
|
717 M | $ 12.64 | -0.16 % | $ 973 M | USA |
 |
Aziyo Biologics
AZYO
|
14.1 M | - | 1.37 % | $ 20.5 M | USA |
 |
Aethlon Medical
AEMD
|
3.24 M | $ 2.53 | 1.41 % | $ 3.95 M | USA |
 |
Myomo
MYO
|
18.4 M | $ 1.01 | -0.49 % | $ 7.12 M | USA |